We report the construction of GAH-conjugated PEG-modified liposomal DXR (ILD) for cancer-targeting therapy and describe the cytotoxic activity of ILD and its targeting ability in a cell-surface-GAH-binding-site-density-dependent manner in both in vitro and in vivo studies against human xenografts. The gene discussed is GDA; the disease is cancer.